SCHEDULE 13G/A: Key Investors Report Zero Beneficial Ownership in Conduit Pharmaceuticals Inc. via Amended SEC Filing

An amended Schedule 13G filing reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited collectively report 0% beneficial ownership in Conduit Pharmaceuticals Inc.

Summary

• This document is Amendment No. 1 to a Schedule 13G filing concerning the beneficial ownership of Common Stock in Conduit Pharmaceuticals Inc. (CUSIP: 20678X106).
• The reporting persons are Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey.
• As of February 19, 2025, each reporting person, and collectively, reported 0.00 shares beneficially owned, representing 0% of the class of securities.
• The reporting entities are related: Nirland Limited is wholly owned by Stockton Limited, which is wholly owned by The Rowland Master Trust, and Dovet Limited is the sole trustee of The Rowland Master Trust.
• The Reporting Persons entered into a Joint Filing Agreement on January 21, 2025, to file this statement and subsequent amendments jointly.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative because the filing indicates a complete divestment (0% beneficial ownership) by a group of related entities, which could be interpreted as a loss of confidence, although no reasons are provided.

Negatives

• The reporting of 0% beneficial ownership implies a complete divestment by these entities, which could be interpreted negatively by the market as a loss of investor confidence, although the document provides no reason for this change.

Comparison to Industry Standards

• This type of ownership disclosure (Schedule 13G amendment reporting 0% beneficial ownership) does not provide information for direct comparison to industry-specific operational or financial benchmarks.

Related Party Transactions

• The filing identifies Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited as related entities due to their ownership structure (Nirland owned by Stockton, Stockton by The Rowland Master Trust, and Dovet as trustee). However, no specific related party transactions with Conduit Pharmaceuticals Inc. are disclosed in this document, only their beneficial ownership status.

Stakeholder Impact

• Shareholders may interpret the complete divestment by this group of investors as a negative signal regarding the company's future prospects or valuation.

Key Dates

Keywords

Conduit Pharmaceuticals Inc., Schedule 13G, beneficial ownership, SEC filing, Nirland Limited, Stockton Limited, The Rowland Master Trust, Dovet Limited, common stock, ownership change, divestment